Is Realty Income the Best Dividend Stock to Buy Long-Term?
Realty Income (NYSE:O) is a longstanding real estate investment trust…
Sell
36
AKBA Quote, Financials, Valuation and Earnings
Last price:
$1.70
Seasonality move
:
9.5%
Day range:
$1.53 - $1.75
52-week range:
$0.80 - $2.89
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.24x
P/B ratio:
--
Volume:
7.7M
Avg. volume:
5.3M
1-year change:
10.39%
Market cap:
$444.1M
Revenue:
$160.2M
EPS (TTM):
-$0.33
Analysts' Opinion
-
Consensus RatingAkebia Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.38, Akebia Therapeutics has an estimated upside of 333.82% from its current price of $1.70.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $1.70.
Fair Value
-
According to the consensus of 2 analysts, Akebia Therapeutics has 333.82% upside to fair value with a price target of $7.38 per share.
AKBA vs. S&P 500
-
Over the past 5 trading days, Akebia Therapeutics has underperformed the S&P 500 by -18.1% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Akebia Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Akebia Therapeutics revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Akebia Therapeutics reported revenues of $46.5M.
Earnings Growth
-
Akebia Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Akebia Therapeutics reported earnings per share of -$0.10.
Enterprise value:
430.9M
EV / Invested capital:
--
Price / LTM sales:
2.24x
EV / EBIT:
--
EV / Revenue:
2.69x
PEG ratio (5yr expected):
-0.34x
EV / Free cash flow:
-10.59x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
86.82x
Gross Profit (TTM):
$97M
Return On Assets:
-31.12%
Net Income Margin (TTM):
-43.33%
Return On Equity:
--
Return On Invested Capital:
-9553.8%
Operating Margin:
-30.77%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $292.6M | $194.6M | $160.2M | $56.2M | $46.5M | |
| Gross Profit | $207.8M | $120.5M | $97M | $37.5M | $26.1M | |
| Operating Income | -$63.8M | -$46.1M | -$50.4M | $1.4M | -$14.3M | |
| EBITDA | -$39.8M | -$8.3M | -$13.7M | $11.4M | -$6.6M | |
| Diluted EPS | -$0.53 | -$0.29 | -$0.33 | $0.00 | -$0.10 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $371.4M | $271.1M | $185.2M | $118.1M | $113.8M | |
| Total Assets | $644.1M | $529.3M | $356.1M | $241.7M | $220.7M | |
| Current Liabilities | $187.1M | $261.1M | $129.5M | $99.9M | $80.9M | |
| Total Liabilities | $396.5M | $455.3M | $350.8M | $272.3M | $269.9M | |
| Total Equity | $247.6M | $74M | $5.2M | -$30.6M | -$49.2M | |
| Total Debt | $96.4M | $97.5M | $66.1M | $34.7M | $38.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$73.2M | -$23.4M | -$40.7M | -$2.3M | -$4.5M | |
| Cash From Investing | -$114K | -- | -$33K | -- | -$2K | |
| Cash From Financing | $14.6M | -$25.2M | $49.7M | -$1.3M | $22.3M | |
| Free Cash Flow | -$73.3M | -$23.4M | -$40.7M | -$2.3M | -$4.5M | |
AKBA
Sector
Market Cap
$444.1M
$33.7M
Price % of 52-Week High
58.82%
40%
Dividend Yield
0%
0%
Shareholder Yield
-9.5%
-0.91%
1-Year Price Total Return
10.39%
-46.85%
Beta (5-Year)
0.866
0.743
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.82
200-day SMA
Buy
Level
$1.67
Bollinger Bands (100)
Sell
Level
1.79 - 2.19
Chaikin Money Flow
Sell
Level
-498.7M
20-day SMA
Sell
Level
$2.01
Relative Strength Index (RSI14)
Sell
Level
39.48
ADX Line
Sell
Level
15.21
Williams %R
Neutral
Level
-75.3337
50-day SMA
Sell
Level
$2.02
MACD (12, 26)
Sell
Level
-0.08
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Sell
Level
-257.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-9.5593)
Sell
CA Score
(Annual)
Level (-4.2798)
Buy
Beneish M-Score
(Annual)
Level (-3.2862)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (6.2745)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Stock Forecast FAQ
In the current month, AKBA has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AKBA average analyst price target in the past 3 months is $7.38.
-
Where Will Akebia Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Akebia Therapeutics share price will rise to $7.38 per share over the next 12 months.
-
What Do Analysts Say About Akebia Therapeutics?
Analysts are divided on their view about Akebia Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Akebia Therapeutics is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Akebia Therapeutics's Price Target?
The price target for Akebia Therapeutics over the next 1-year time period is forecast to be $7.38 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AKBA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Akebia Therapeutics is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AKBA?
You can purchase shares of Akebia Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Akebia Therapeutics shares.
-
What Is The Akebia Therapeutics Share Price Today?
Akebia Therapeutics was last trading at $1.70 per share. This represents the most recent stock quote for Akebia Therapeutics. Yesterday, Akebia Therapeutics closed at $1.70 per share.
-
How To Buy Akebia Therapeutics Stock Online?
In order to purchase Akebia Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Archer Aviation a Buy, Sell or Hold?
Vertical takeoff and landing (eVTOL) aircraft sound futuristic but that’s…
Down 50%, Is Dell Technologies a Buy?
Dell (NYSE:DELL)’s share price has been on a roller coaster…
Stock Ideas
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
33
BULZ alert for Apr 10
MicroSectors Solactive FANG & Innov 3X Levd ETN [BULZ] is down 12.85% over the past day.
Sell
31
TECS alert for Apr 10
Direxion Daily Technology Bear 3x Shares [TECS] is up 11.17% over the past day.
Sell
48
FNGA alert for Apr 10
MicroSectors FANG+ Index 3X Leveraged ETN [FNGA] is down 11.06% over the past day.
